BUZZ-Street View: New growth drivers show promise to boost Medtronic's revenue

Reuters

02-20

BUZZ-Street View: New growth drivers show promise to boost Medtronic's revenue

** Medtronic on Tuesday missed Wall Street estimates for third-quarter revenue due to lower purchases of its surgical devices by distributors, and said the problems would persist in the current quarter

PLETHORA OF CATALYSTS AT PLAY

** J.P. Morgan ("Neutral", PT: $95) says there are reasons to stay more positive into FY26 with growth in co's diabetes and heart device business, along with contribution from new products which are used for procedures such as renal denervation and pulsed field ablation

** RBC Capital markets ("Outperform", PT: $105) says MDT has "plethora of catalysts at play" including its surgical robot Hugo and expansion in its portfolio for cardiac devices, along with significant opportunity in renal denervation

** UBS ("Neutral", PT: $95) sees potential for continued improvement in diabetes segment

** Citi ("Neutral", PT: $92) says Medtronic is standing on the threshold of several new growth drivers that are starting to gain traction

(Reporting by Siddhi Mahatole)

((Siddhiprabhanjan.mahatole@thomsonreuters.com))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2512846454"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2512846454\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2512846454?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-20 00:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2512846454","market":"us","top_or_hot":-1,"title":"BUZZ-Street View: New growth drivers show promise to boost Medtronic's revenue","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Street View: New growth drivers show promise to boost Medtronic's revenue</title></head><body><p>** Medtronic <span>on Tuesday</span> missed Wall Street estimates for third-quarter revenue due to lower purchases of its surgical devices by distributors, and said the problems would persist in the current quarter</p><p>PLETHORA OF CATALYSTS AT PLAY</p><p>** J.P. Morgan (\"Neutral\", PT: $95) says there are reasons to stay more positive into FY26 with growth in co's diabetes and heart device business, along with contribution from new products which are used for procedures such as renal denervation and pulsed field ablation</p><p>** RBC Capital markets (\"Outperform\", PT: $105) says MDT has \"plethora of catalysts at play\" including its surgical robot Hugo and expansion in its portfolio for cardiac devices, along with significant opportunity in renal denervation</p><p>** UBS (\"Neutral\", PT: $95) sees potential for continued improvement in diabetes segment</p><p>** Citi (\"Neutral\", PT: $92) says Medtronic is standing on the threshold of several new growth drivers that are starting to gain traction</p><p> (Reporting by Siddhi Mahatole)</p><p> ((Siddhiprabhanjan.mahatole@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Street View: New growth drivers show promise to boost Medtronic's revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Street View: New growth drivers show promise to boost Medtronic's revenue\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-02-20 00:34</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Street View: New growth drivers show promise to boost Medtronic's revenue</title></head><body><p>** Medtronic <span>on Tuesday</span> missed Wall Street estimates for third-quarter revenue due to lower purchases of its surgical devices by distributors, and said the problems would persist in the current quarter</p><p>PLETHORA OF CATALYSTS AT PLAY</p><p>** J.P. Morgan (\"Neutral\", PT: $95) says there are reasons to stay more positive into FY26 with growth in co's diabetes and heart device business, along with contribution from new products which are used for procedures such as renal denervation and pulsed field ablation</p><p>** RBC Capital markets (\"Outperform\", PT: $105) says MDT has \"plethora of catalysts at play\" including its surgical robot Hugo and expansion in its portfolio for cardiac devices, along with significant opportunity in renal denervation</p><p>** UBS (\"Neutral\", PT: $95) sees potential for continued improvement in diabetes segment</p><p>** Citi (\"Neutral\", PT: $92) says Medtronic is standing on the threshold of several new growth drivers that are starting to gain traction</p><p> (Reporting by Siddhi Mahatole)</p><p> ((Siddhiprabhanjan.mahatole@thomsonreuters.com))</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDT","symbol_name":"美敦力","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250219:nL3N3PA0SA:1","article_id":"2512846454","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2512846454","pubTimestamp":1739982885,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Street View: New growth drivers show promise to boost Medtronic's revenue** Medtronic on Tuesday missed Wall Street estimates for third-quarter revenue due to lower purchases of its surgical devi","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MDT":"美敦力"},"translate_title":"BUZZ-Street View：新的增长动力有望增加美敦力的收入","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDT":0.9},"content_text":"BUZZ-Street View: New growth drivers show promise to boost Medtronic's revenue** Medtronic on Tuesday missed Wall Street estimates for third-quarter revenue due to lower purchases of its surgical devices by distributors, and said the problems would persist in the current quarterPLETHORA OF CATALYSTS AT PLAY** J.P. Morgan (\"Neutral\", PT: $95) says there are reasons to stay more positive into FY26 with growth in co's diabetes and heart device business, along with contribution from new products which are used for procedures such as renal denervation and pulsed field ablation** RBC Capital markets (\"Outperform\", PT: $105) says MDT has \"plethora of catalysts at play\" including its surgical robot Hugo and expansion in its portfolio for cardiac devices, along with significant opportunity in renal denervation** UBS (\"Neutral\", PT: $95) sees potential for continued improvement in diabetes segment** Citi (\"Neutral\", PT: $92) says Medtronic is standing on the threshold of several new growth drivers that are starting to gain traction (Reporting by Siddhi Mahatole) ((Siddhiprabhanjan.mahatole@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1}}}